Dana-Farber Beth Israel Deaconess Cancer Collaboration

For 75 years, Dana-Farber has been at the forefront of blending exceptional cancer care with leading-edge, transformative science.

Now, delivering on our long-held vision, Dana-Farber announced a collaboration with Beth Israel Deaconess Medical Center (BIDMC), a Harvard-affiliated academic medical center, and its affiliated physician group, Harvard Medical Faculty Physicians (HMFP).

Together, we proposed a new adult inpatient hospital, dedicated exclusively to the needs of cancer patients.

Dana-Farber Beth Israel Deaconess Cancer Collaboration Announcement

Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center (BIDMC) announced plans for a comprehensive new collaboration designed to advance the future of cancer care and build the region’s only independent, free-standing inpatient hospital for adult cancer patients.

About the Proposed Inpatient Hospital Building

The Dana-Farber Beth Israel Deaconess Cancer Collaboration will advance Dana-Farber's long-term goal of creating a fully integrated oncology campus for adult inpatient and outpatient care, as well as research. The freestanding, state-of-the-art facility will be owned and operated by Dana-Farber. The proximity to our outpatient and research facilities in Longwood supports our continued bench-to-bedside research model.

Designed Specifically for Cancer Care

The new inpatient building will offer many benefits, including:

An enhanced patient experience in an inpatient facility focused solely on the needs of oncology patients.
A state-of-the-art facility that can adapt to the rapid advances in oncology care.
Additional beds to meet the growing incidences of cancer and ensure timely access to care.
Seamless, integrated care supported by teams of Dana-Farber, BIDMC, and HMFP clinicians.

About Our Collaboration

Every day, our clinicians and researchers discover important new approaches to prevent, treat, and cure cancer. This new collaboration ensures that our inpatient facilities and clinical collaborations will be designed and positioned for the future of cancer care.

BIDMC shares our vision to create a forward-looking model of cancer care that further advances the patient and caregiver experience, expands access to value-driven care and fosters scientific discovery. Their shared vision and legacy of excellence makes them a terrific partner for us.

Our world-leading discoveries will best serve patients in a state-of-the-art hospital, equipped to adapt to rapidly changing technology and designed solely to support cancer patients. With our plans for a new adult inpatient cancer hospital, Dana-Farber and Beth Israel together will be able to manage all aspects of cancer care for our patients and their loved ones in the Longwood Medical area.

Timeline and What to Expect

We anticipate several years of careful planning to finalize our model, obtain regulatory approvals, and build the new inpatient hospital.

Here's what you can expect as we transition to this new patient care model.

There will be no changes in patient care at this time, and we do not anticipate any changes for several years.

Will this change impact inpatient care today?

No. Nothing is changing today. Dana-Farber's current affiliation with Brigham and Women's Hospital (BWH) for adult inpatient medical and surgical oncology care will continue through this transition.

The inpatient facilities and clinical collaborations that are in place today through our relationship with BWH provide excellent patient care and outcomes. We have deep respect and profound appreciation for our Brigham and Women's Hospital colleagues, and we are confident that we will continue to work together to provide an exceptional patient experience. This will continue for many years while we work on this transition.

Once the Dana-Farber Beth Israel Deaconess Cancer Collaboration is operational, patient care will continue to be led by Dana-Farber clinicians, delivered in the new inpatient hospital.

Will this impact outpatient care facilities?

All Dana-Farber outpatient oncology care will continue to be provided at our clinics in the Boston area and at our other regional campuses in Massachusetts and New Hampshire.

Will this impact pediatric care?

Our joint program for pediatric cancer care with Boston Children's Hospital will continue without change or interruption.

For Donors and Supporters of Dana-Farber

Dana-Farber and Beth Israel Deaconess will remain fully independent organizations, with separate boards of trustees, leadership, and fundraising. All philanthropic contributions to Dana-Farber will continue to fund Dana-Farber initiatives.

More information for donors and supporters

Legal Notices

Oct. 10, 2023 - Notice of Intent: Public Announcement Concerning a Proposed Health Care Project

In the News

Thank you for your trust in Dana-Farber. It is our mission of caring for you, your family, and our community that inspired this visionary new collaboration with BIDMC. We will continue to update this page with details of this exciting new collaboration as our plans progress.